Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of EpilepsyGlobeNewsWire • 11/06/25
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome TherapeuticsGlobeNewsWire • 11/06/25
Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis ChangerSeeking Alpha • 11/05/25
Axsome Therapeutics Stock In A Buy Zone. Analysts See Profit On The Horizon.Investors Business Daily • 11/05/25
AXSM Q3 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity SalesZacks Investment Research • 11/04/25
Axsome Therapeutics (AXSM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseZacks Investment Research • 10/27/25
Halper Sadeh LLC Encourages Axsome Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their RightsBusiness Wire • 10/24/25
Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy RatingSeeking Alpha • 10/10/25
Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy CommunityGlobeNewsWire • 10/09/25
Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3GlobeNewsWire • 10/07/25
Prediction: These 2 Under-the-Radar Stocks Could Beat the Market in the Next 5 YearsThe Motley Fool • 09/30/25
Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit TranscriptSeeking Alpha • 09/18/25
Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025GlobeNewsWire • 09/17/25
Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/08/25
AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/YZacks Investment Research • 08/05/25